Literature DB >> 19018879

Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients.

P Ryan1, F Blanco, P García-Gascó, Ja García-Merchán, E Vispo, P Barreiro, P Labarga, J González-Lahoz, V Soriano.   

Abstract

OBJECTIVE: Multiple factors may lead to hepatic steatosis (HS) in HIV-positive patients. HS may result in severe liver damage on its own and/or by accelerating the progression of chronic viral hepatitis B or C.
METHODS: The sensitivity/specificity of liver ultrasound (US) to recognize severe HS is above 85%. A cross-sectional case-control study of all HIV out-patients who underwent liver US since 2004 was conducted at our institution.
RESULTS: Eight hundred and thirty (36.1%) out of 2300 HIV-positive patients on regular follow-up underwent liver US during the study period. Severe HS was diagnosed in 108 (13%) patients. A total of 117 matched HIV controls lacking HS were selected randomly. In patients with severe HS, we found significantly higher values of body mass index (BMI), plasma viral load, serum glucose, alkaline phosphatase, triglycerides and low-density lipoprotein cholesterol, as well as significantly higher prevalence of diabetes, elevated alcohol consumption, lipohypertrophy and advanced liver fibrosis. Furthermore, a trend towards longer exposure to nucleoside analogues was noticed. In the multivariate analysis, only elevated alcohol consumption [odds ratio (OR) 7, P=0.013], lipohypertrophy (OR 5.3, P=0.008), plasma viral load (OR 2.1, P=0.02), BMI (OR 1.2, P=0.013) and serum glucose (OR 1.03, P=0.027) were significantly associated with severe HS.
CONCLUSIONS: Severe HS in HIV-positive patients is associated with predisposing factors that are similar to those of HIV-negative individuals. However, its characteristic association with elevated plasma viral load might suggest a direct involvement of HIV in liver fat deposition. Therefore, the benefit of controlling HIV replication with antiretroviral therapy should be balanced against its effect of occasionally inducing metabolic abnormalities and lipodystrophy.

Entities:  

Mesh:

Year:  2008        PMID: 19018879     DOI: 10.1111/j.1468-1293.2008.00651.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  8 in total

Review 1.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

2.  Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.

Authors:  Jennifer C Price; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien
Journal:  Hepatology       Date:  2017-02-03       Impact factor: 17.425

3.  Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons.

Authors:  Todd T Brown; Shruti H Mehta; Catherine Sutcliffe; Yvonne Higgins; Michael S Torbenson; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

4.  Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.

Authors:  V Borghi; L Bisi; L Manzini; A Cossarizza; C Mussini
Journal:  Infection       Date:  2012-12-09       Impact factor: 3.553

5.  Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.

Authors:  Michelle DallaPiazza; Valerianna K Amorosa; Russell Localio; Jay R Kostman; Vincent Lo Re
Journal:  BMC Infect Dis       Date:  2010-05-13       Impact factor: 3.090

6.  Risk factors for fatty liver in the Multicenter AIDS Cohort Study.

Authors:  Jennifer C Price; Eric C Seaberg; Rachel Latanich; Matthew J Budoff; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Wendy S Post; Chloe L Thio
Journal:  Am J Gastroenterol       Date:  2014-03-18       Impact factor: 10.864

7.  Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients.

Authors:  Giada Sebastiani; Kathleen C Rollet-Kurhajec; Costa Pexos; Norbert Gilmore; Marina B Klein
Journal:  Open Forum Infect Dis       Date:  2015-02-23       Impact factor: 3.835

Review 8.  Liver as a target of human immunodeficiency virus infection.

Authors:  Murali Ganesan; Larisa Y Poluektova; Kusum K Kharbanda; Natalia A Osna
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.